1 Subgroup analysis ‐ different antipsychotic drugs (short term) |
40 |
2132 |
Risk Ratio (M‐H, Random, 95% CI) |
0.93 [0.87, 1.00] |
1.1 Bromperidol |
8 |
458 |
Risk Ratio (M‐H, Random, 95% CI) |
1.01 [0.88, 1.15] |
1.2 Clopenthixol |
2 |
92 |
Risk Ratio (M‐H, Random, 95% CI) |
0.77 [0.52, 1.12] |
1.3 Droperidol |
2 |
85 |
Risk Ratio (M‐H, Random, 95% CI) |
0.87 [0.73, 1.04] |
1.4 Flupenthixol |
1 |
21 |
Risk Ratio (M‐H, Random, 95% CI) |
0.08 [0.01, 1.32] |
1.5 Fluphenazine |
3 |
157 |
Risk Ratio (M‐H, Random, 95% CI) |
0.78 [0.37, 1.65] |
1.6 Loxapine |
3 |
162 |
Risk Ratio (M‐H, Random, 95% CI) |
1.12 [0.87, 1.44] |
1.7 Molindone |
1 |
30 |
Risk Ratio (M‐H, Random, 95% CI) |
0.13 [0.01, 2.25] |
1.8 Nemonapride |
1 |
167 |
Risk Ratio (M‐H, Random, 95% CI) |
0.55 [0.33, 0.93] |
1.9 Perphenazine |
1 |
39 |
Risk Ratio (M‐H, Random, 95% CI) |
0.7 [0.41, 1.20] |
1.10 Pimozide |
3 |
72 |
Risk Ratio (M‐H, Random, 95% CI) |
1.09 [0.74, 1.61] |
1.11 Pipotiazine |
3 |
134 |
Risk Ratio (M‐H, Random, 95% CI) |
0.89 [0.39, 2.02] |
1.12 Sulpiride |
1 |
74 |
Risk Ratio (M‐H, Random, 95% CI) |
0.83 [0.50, 1.39] |
1.13 Tiopropazate |
1 |
86 |
Risk Ratio (M‐H, Random, 95% CI) |
1.07 [0.73, 1.57] |
1.14 Thiothixene |
2 |
83 |
Risk Ratio (M‐H, Random, 95% CI) |
1.03 [0.70, 1.52] |
1.15 Timiperone |
1 |
206 |
Risk Ratio (M‐H, Random, 95% CI) |
0.80 [0.57, 1.11] |
1.16 Trifluoperazine |
4 |
124 |
Risk Ratio (M‐H, Random, 95% CI) |
1.01 [0.68, 1.50] |
1.17 Trifluperidol |
1 |
39 |
Risk Ratio (M‐H, Random, 95% CI) |
0.96 [0.53, 1.71] |
1.18 Zuclopenthixol |
2 |
103 |
Risk Ratio (M‐H, Random, 95% CI) |
0.94 [0.70, 1.28] |
2 Subgroup analysis ‐ different antipsychotic drugs (medium term) |
1 |
80 |
Risk Ratio (M‐H, Random, 95% CI) |
0.51 [0.37, 0.69] |
2.1 Thiothixene |
1 |
80 |
Risk Ratio (M‐H, Random, 95% CI) |
0.51 [0.37, 0.69] |
3 Subgroup analysis ‐ treatment‐resistant participants (short term) |
40 |
2132 |
Risk Ratio (M‐H, Random, 95% CI) |
0.93 [0.87, 1.00] |
3.1 Trials with treatment‐resistant participants |
3 |
130 |
Risk Ratio (M‐H, Random, 95% CI) |
1.46 [0.66, 3.23] |
3.2 Trials without treatment‐resistant participants |
37 |
2002 |
Risk Ratio (M‐H, Random, 95% CI) |
0.93 [0.87, 1.00] |